217 related articles for article (PubMed ID: 10768989)
21. Role of Pseudomonas aeruginosa type III effectors in disease.
Engel J; Balachandran P
Curr Opin Microbiol; 2009 Feb; 12(1):61-6. PubMed ID: 19168385
[TBL] [Abstract][Full Text] [Related]
22. Identification of superoxide dismutase as a cofactor for the pseudomonas type III toxin, ExoU.
Sato H; Feix JB; Frank DW
Biochemistry; 2006 Aug; 45(34):10368-75. PubMed ID: 16922513
[TBL] [Abstract][Full Text] [Related]
23. Alveolar response to Pseudomonas aeruginosa: role of the type III secretion system.
Ader F; Le Berre R; Faure K; Gosset P; Epaulard O; Toussaint B; Polack B; Nowak E; Viget NB; Kipnis E; Guery BP
Infect Immun; 2005 Jul; 73(7):4263-71. PubMed ID: 15972518
[TBL] [Abstract][Full Text] [Related]
24. Type III secretion system-associated toxins, proteases, serotypes, and antibiotic resistance of Pseudomonas aeruginosa isolates associated with keratitis.
Zhu H; Conibear TC; Bandara R; Aliwarga Y; Stapleton F; Willcox MD
Curr Eye Res; 2006 Apr; 31(4):297-306. PubMed ID: 16603462
[TBL] [Abstract][Full Text] [Related]
25. Quorum sensing negatively controls type III secretion regulon expression in Pseudomonas aeruginosa PAO1.
Bleves S; Soscia C; Nogueira-Orlandi P; Lazdunski A; Filloux A
J Bacteriol; 2005 Jun; 187(11):3898-902. PubMed ID: 15901720
[TBL] [Abstract][Full Text] [Related]
26. Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent.
Bjarnsholt T; Jensen PØ; Burmølle M; Hentzer M; Haagensen JAJ; Hougen HP; Calum H; Madsen KG; Moser C; Molin S; Høiby N; Givskov M
Microbiology (Reading); 2005 Feb; 151(Pt 2):373-383. PubMed ID: 15699188
[TBL] [Abstract][Full Text] [Related]
27. Early immune response to the components of the type III system of Pseudomonas aeruginosa in children with cystic fibrosis.
Corech R; Rao A; Laxova A; Moss J; Rock MJ; Li Z; Kosorok MR; Splaingard ML; Farrell PM; Barbieri JT
J Clin Microbiol; 2005 Aug; 43(8):3956-62. PubMed ID: 16081936
[TBL] [Abstract][Full Text] [Related]
28. Interactions between effector proteins of the Pseudomonas aeruginosa type III secretion system do not significantly affect several measures of disease severity in mammals.
Shaver CM; Hauser AR
Microbiology (Reading); 2006 Jan; 152(Pt 1):143-152. PubMed ID: 16385124
[TBL] [Abstract][Full Text] [Related]
29. Difference of Type 3 secretion system (T3SS) effector gene genotypes (exoU and exoS) and its implication to antibiotics resistances in isolates of Pseudomonas aeruginosa from chronic otitis media.
Park MH; Kim SY; Roh EY; Lee HS
Auris Nasus Larynx; 2017 Jun; 44(3):258-265. PubMed ID: 27461174
[TBL] [Abstract][Full Text] [Related]
30. A leucine-rich motif targets Pseudomonas aeruginosa ExoS within mammalian cells.
Zhang Y; Barbieri JT
Infect Immun; 2005 Dec; 73(12):7938-45. PubMed ID: 16299285
[TBL] [Abstract][Full Text] [Related]
31. Antimicrobial susceptibility pattern and distribution of exoU and exoS in clinical isolates of Pseudomonas aeruginosa at a Malaysian hospital.
Idris SN; Desa MN; Aziz MN; Taib NM
Southeast Asian J Trop Med Public Health; 2012 Jan; 43(1):116-23. PubMed ID: 23082561
[TBL] [Abstract][Full Text] [Related]
32. ExoU is a potent intracellular phospholipase.
Sato H; Frank DW
Mol Microbiol; 2004 Sep; 53(5):1279-90. PubMed ID: 15387809
[TBL] [Abstract][Full Text] [Related]
33. The Pseudomonas aeruginosa type III secreted toxin ExoT is necessary and sufficient to induce apoptosis in epithelial cells.
Shafikhani SH; Morales C; Engel J
Cell Microbiol; 2008 Apr; 10(4):994-1007. PubMed ID: 18053004
[TBL] [Abstract][Full Text] [Related]
34. Pseudomonas aeruginosa mediated apoptosis requires the ADP-ribosylating activity of exoS.
Kaufman MR; Jia J; Zeng L; Ha U; Chow M; Jin S
Microbiology (Reading); 2000 Oct; 146 ( Pt 10)():2531-2541. PubMed ID: 11021928
[TBL] [Abstract][Full Text] [Related]
35. High frequency of the exoU+/exoS+ genotype associated with multidrug-resistant "high-risk clones" of Pseudomonas aeruginosa clinical isolates from Peruvian hospitals.
Horna G; Amaro C; Palacios A; Guerra H; Ruiz J
Sci Rep; 2019 Jul; 9(1):10874. PubMed ID: 31350412
[TBL] [Abstract][Full Text] [Related]
36. Activation of the Pseudomonas aeruginosa type III secretion system requires an intact pyruvate dehydrogenase aceAB operon.
Dacheux D; Epaulard O; de Groot A; Guery B; Leberre R; Attree I; Polack B; Toussaint B
Infect Immun; 2002 Jul; 70(7):3973-7. PubMed ID: 12065547
[TBL] [Abstract][Full Text] [Related]
37. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
Hauser AR; Cobb E; Bodi M; Mariscal D; Vallés J; Engel JN; Rello J
Crit Care Med; 2002 Mar; 30(3):521-8. PubMed ID: 11990909
[TBL] [Abstract][Full Text] [Related]
38. Type III Secretion System of Pseudomonas aeruginosa Affects Matrix Metalloproteinase 12 (MMP-12) and MMP-13 Expression via Nuclear Factor κB Signaling in Human Carcinoma Epithelial Cells and a Pneumonia Mouse Model.
Park JW; Kim YJ; Shin IS; Kwon OK; Hong JM; Shin NR; Oh SR; Ha UH; Kim JH; Ahn KS
J Infect Dis; 2016 Sep; 214(6):962-9. PubMed ID: 27377745
[TBL] [Abstract][Full Text] [Related]
39. Structural basis of cytotoxicity mediated by the type III secretion toxin ExoU from Pseudomonas aeruginosa.
Gendrin C; Contreras-Martel C; Bouillot S; Elsen S; Lemaire D; Skoufias DA; Huber P; Attree I; Dessen A
PLoS Pathog; 2012; 8(4):e1002637. PubMed ID: 22496657
[TBL] [Abstract][Full Text] [Related]
40. Immuno-modulatory functions of the type-3 secretion system and impacts on the pulmonary host defense: A role for ExoS of Pseudomonas aeruginosa in cystic fibrosis.
Belmadi N; Wu Y; Touqui L
Toxicon; 2018 Mar; 143():68-73. PubMed ID: 29339019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
